David John Simpson
Directeur Général chez Iksuda Therapeutics Ltd.
Profil
David John Simpson is the founder and CEO of Iksuda Therapeutics Ltd., which was founded in 2007.
He is currently a Non-Executive Director at Leaf Systems International Ltd.
Dr. Simpson has held former positions as a Principal Scientist at ML Laboratories Plc, Senior Scientist at Cobra Therapeutics Ltd., Head-Process Development at Allergan Biologics Ltd., Principal at Allergan Ltd.
(Ireland), and Principal at Cobra Biologics Ltd.
Postes actifs de David John Simpson
| Sociétés | Poste | Début |
|---|---|---|
Iksuda Therapeutics Ltd.
 Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Directeur Général | 01/02/2014 |
Leaf Systems International Ltd.
 Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | Directeur/Membre du Conseil | - |
Anciens postes connus de David John Simpson
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGAN PLC | Corporate Officer/Principal | - |
Cobra Biologics Ltd.
 Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Corporate Officer/Principal | - |
| ML Laboratories Plc | Corporate Officer/Principal | - |
Cobra Therapeutics Ltd.
 Cobra Therapeutics Ltd. Medical SpecialtiesHealth Technology Cobra Therapeutics Ltd. manufactured cancer therapeutics on contract basis. It also developed gene delivery and expression technologies. The company was founded in 1992 and was headquartered in Keele, UK | Corporate Officer/Principal | - |
Allergan Biologics Ltd.
 Allergan Biologics Ltd. BiotechnologyHealth Technology Part of Pharmaron Beijing Co., Ltd., Allergan Biologics Ltd. develops biologics products. The company is based in Liverpool, UK. The British company was founded in 2002 by Bernard Chan. Allergan Biologics was acquired by Pharmaron Biologics (UK) Holdings Ltd. from AbbVie, Inc. on April 30, 2021 for $165.95 million. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
| ML Laboratories Plc | Commercial Services |
Cobra Therapeutics Ltd.
Cobra Therapeutics Ltd. Medical SpecialtiesHealth Technology Cobra Therapeutics Ltd. manufactured cancer therapeutics on contract basis. It also developed gene delivery and expression technologies. The company was founded in 1992 and was headquartered in Keele, UK | Health Technology |
Allergan Biologics Ltd.
Allergan Biologics Ltd. BiotechnologyHealth Technology Part of Pharmaron Beijing Co., Ltd., Allergan Biologics Ltd. develops biologics products. The company is based in Liverpool, UK. The British company was founded in 2002 by Bernard Chan. Allergan Biologics was acquired by Pharmaron Biologics (UK) Holdings Ltd. from AbbVie, Inc. on April 30, 2021 for $165.95 million. | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Cobra Biologics Ltd.
Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Health Technology |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Health Technology |
Leaf Systems International Ltd.
Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | Health Technology |
